Advertisement

Topics

OMEICOS Therapeutics Company Profile

19:37 EST 9th December 2018 | BioPortfolio

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS’ technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Müller and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com.


News Articles [698 Associated News Articles listed on BioPortfolio]

OMEICOS Therapeutics Closes €17m Series C Financing

OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today a...

OMEICOS closes €17mm Series C

OMEICOS Therapeutics GMBH (small-molecule therapies for cardiovascular and ophthalmic diseases) raised €17mm ($19.5mm) in its Series C financing led by new backer Forbion, which was joined by return...

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and ...

-- High-resolution electrocardiography strongly supports OMT-28’s claim for low pro-arrhythmic risk -- Read more...

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

-- High-resolution electrocardiography strongly supports OMT-28’s claim for low pro-arrhythmic risk -- OMEICOS Therapeutics, a Berlin-based biopharmaceutical company ...

OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation

-- Proceeds provide OMEICOS with the financial runway to conduct the Phase II Study PROMISE-AF and continue expansion into ophthalmology through US subsidiary -- OMEICO...

Forbion Leads €17M Series C Financing of Omeicos Therapeutics

Forbion invests €12.5m from its recently launched Forbion IV fund OMEICOS is pioneering the development of stable analogs of omega-3 fatty acid metabol...

Series C Bags German Company €17M for Irregular Heartbeat Treatment

Omeicos Therapeutics has secured €17M in a Series C round to fund clinical development of its lead treatment for irregular heartbeat. Robert Fischer, CEO of the German biopharmaceutical company, tol...

OMEICOS Therapeutics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 10052018] Prices from USD $250

SummaryOMEICOS Therapeutics GmbH OMEICOS is a biopharmaceutical company that develops small molecule therapeutics. The company utilizes its proprietary technology of the body's own omega3 fatty acid m...

PubMed Articles [457 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1282 Associated Companies listed on BioPortfolio]

OMEICOS Therapeutics GmbH

OMEICOS Therapeutics is a spin-off company from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synt...

OMEICOS Therapeutics

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthe...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "OMEICOS Therapeutics" on BioPortfolio

We have published hundreds of OMEICOS Therapeutics news stories on BioPortfolio along with dozens of OMEICOS Therapeutics Clinical Trials and PubMed Articles about OMEICOS Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OMEICOS Therapeutics Companies in our database. You can also find out about relevant OMEICOS Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record